This document is an excerpt from the EUR-Lex website
Document 52018M8889
Prior notification of a concentration (Case M.8889 — Teva/PGT OTC Assets) (Text with EEA relevance. )
Prior notification of a concentration (Case M.8889 — Teva/PGT OTC Assets) (Text with EEA relevance. )
Prior notification of a concentration (Case M.8889 — Teva/PGT OTC Assets) (Text with EEA relevance. )
OJ C 187, 1.6.2018, p. 6–6
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
1.6.2018 |
EN |
Official Journal of the European Union |
C 187/6 |
Prior notification of a concentration
(Case M.8889 — Teva/PGT OTC Assets)
(Text with EEA relevance)
(2018/C 187/06)
1.
On 25 May 2018, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).This notification concerns the following undertakings:
|
— |
Teva Pharmaceuticals Industries Ltd (‘Teva’, Israel), |
|
— |
Part of the over-the-counter (‘OTC’) business that Teva previously contributed to a joint venture (‘PGT’) controlled by The Procter & Gamble Company (‘P&G’, United States) (‘Target’). |
Teva acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the Target.
The concentration is accomplished by way of contract or any other means.
2.
The business activities of the undertakings concerned are:— for Teva: global pharmaceutical company involved in the development, production and marketing of generic and proprietary pharmaceutical products, as well as biopharmaceuticals and active pharmaceutical ingredients,
— for Target: number of OTC pharmaceutical products previously contributed by Teva to PGT, including marginal sales in cosmetic products, medical devices, food supplements and general articles.
3.
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.
4.
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.8889 — Teva/PGT OTC Assets
Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:
|
Email: COMP-MERGER-REGISTRY@ec.europa.eu |
|
Fax +32 22964301 |
|
Postal address: |
|
European Commission |
|
Directorate-General for Competition |
|
Merger Registry |
|
1049 Bruxelles/Brussel |
|
BELGIQUE/BELGIË |
(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).